ADMA - ADMA Biologics: Feeling Bullish After Encouraging Q2 Earnings Report

• ADMA reported their Q2 earnings that revealed a 129% increase year-over-year in revenues. In addition, the company reduced their net loss, while improving gross margins.
• ADMA expects to pull in $100M or more in revenue during 2021 and is sticking to their plans to expand their plasma collection network despite the pandemic.
• Management expects the company to pull in around $300M or more and be profitable beginning no later than the first quarter of 2024.
• ADMA continues to trade at a significant discount compared to its peers. I believe that the pandemic is weighing the ticker down and could be a lingering threat for an extended period of time.
• I am feeling extremely bullish about ADMA’s long-term upside and will continue accumulating shares on dips in the share price.

For further details see: